Wegovy contains semaglutide, a GLP-1 receptor agonist that helps reduce appetite, slows gastric emptying, and signals fullness. It is an FDA-approved finished prescription product for chronic weight management in adults who meet its clinical criteria.
Rivas provides the medical supervision rather than simply writing a prescription. Your provider reviews your health, manages the prescription, and follows your progress at monthly visits. Medication is filled and paid for separately through a pharmacy or NovoCare.
Patients who are already taking Wegovy can bring their current dose information. The provider reviews their history, response, and tolerability and, when clinically appropriate, continues or adjusts their care without automatically restarting treatment.